Sage Journals: Discover world-class research

Abstract

Objective

This study investigated the effect of preoperative double-J stent placement on stone recurrence following flexible ureteroscopic lithotripsy and analyzed the risk factors for postoperative stone recurrence. The study aimed to provide a clinical reference for better management of the identified risk factors.

Methods

This retrospective study collected data from patients who underwent flexible ureteroscopic lithotripsy for urinary stones between April 2023 and May 2024. Patients were divided into two groups based on whether a double-J stent was placed preoperatively. Comparisons were made between the stent and nonstent groups. Univariate and multivariate logistic regression analyses were performed to identify the risk factors for postoperative stone recurrence.

Results

The recurrence rate was 19.51% in the nonstent group and 1.47% in the stent group, with a statistically significant difference (P = 0.001). Stone removal strategy (P < 0.001), preoperative systolic blood pressure (P = 0.017), and intraoperative blood loss (P = 0.044) were identified as risk factors for postoperative recurrence, with stone removal strategy (P = 0.013) and preoperative systolic blood pressure (P = 0.017) being independent risk factors.

Conclusions

Preoperative placement of a double-J stent is associated with a lower recurrence rate of stones following flexible ureteroscopic lithotripsy than no preoperative stenting. Stone removal strategy and preoperative systolic blood pressure are independent risk factors for stone recurrence following flexible ureteroscopic lithotripsy.

Keywords

Kidney stones upper urinary tract stones flexible ureteroscopic lithotripsy risk factors double-J stent

Introduction

Urinary stones are extremely common, affecting approximately 10% of the global population, and its incidence is steadily increasing each year.^1,2 Apart from obstruction and infections caused by the stones themselves as well as complications associated with surgical interventions, urinary stones increase the risk of chronic kidney disease, coronary heart disease, and mortality^.^3,4 Currently, treatments for urinary stones are classified into surgical and nonsurgical methods. The main minimally invasive surgical methods include flexible ureteroscopic lithotripsy (FURSL) and percutaneous nephrolithotomy (PCNL).⁵

Although PCNL is effective in the treatment of upper urinary tract stones, it is limited by its substantial trauma and high incidence of complications such as bleeding^6,7 FURSL may be considered a better treatment modality than PCNL for kidney stones with a diameter of ≤2 cm.⁸ Stone removal surgeries such as PCNL and FURSL are associated with the risks of postoperative residual stones and recurrence, warranting subsequent secondary surgery.⁹

It is necessary to explore whether preoperative placement of double-J (DJ) stents affects the stone recurrence rate following FURSL. Current studies mainly focus on the impact of preoperative ureteral stent placement on the stone clearance rate, and no study has explored whether preoperative ureteral stent placement affects postoperative stone recurrence. Shields et al.¹⁰ demonstrated that preoperative ureteral stenting is positively correlated with the success rate of minimally invasive stone removal. Jeong et al.¹¹ also revealed that preoperative ureteral stent placement improved the success rate of ureteral sheath placement, thereby increasing the stone clearance rates. This study investigated the relationship between preoperative ureteral stent placement and postoperative stone recurrence, aiming to clarify whether preoperative ureteral stent placement is conducive to reducing the postoperative stone recurrence rate.

This study analyzed the factors influencing stone recurrence following FURSL to provide reference evidence for clinicians to better manage risk factors, reduce the postoperative recurrence rates, and improve the patient quality of life.

Methods

Study population

A total of 109 patients with kidney and upper ureteral stones underwent FURSL in the Department of Urology at Peking University First Hospital–Miyun Hospital between April 2023 and May 2024. Among them, 41 (37.61%) underwent FURSL without DJ tubes and 68 (62.39%) underwent FURSL with DJ tubes. Clinical and follow-up data were collected. Clinical data included general demographic information, perioperative data, stone diameter, and postoperative stone clearance rates.

The recurrence of stones is defined as the recurrence clearly identified by imaging, that is, no residual stone with a diameter of <3 mm detected by B-ultrasound or computed tomography (CT) within 1 week after the operation as well as new stones being detected on subsequent B-ultrasound or CT. This study considered the recurrence of stones within half a year as the clinical outcome.

The inclusion criteria were as follows: (a) kidney or ureteral stones confirmed by ultrasound, intravenous urography, or CT; (b) single stones; (c) stone diameter ≤2 cm; (d) patients undergoing FURSL; and (e) complete baseline and follow-up data. The exclusion criteria were as follows: (a) coagulopathy and (b) cardiac dysfunction precluding surgery.

This study’s clinical variables included sex, age, body mass index, diabetes, hypertension, coronary heart disease, stone diameter, side (left or right), stone location, stone removal strategy, operative time, intraoperative blood loss, blood pressure, and hematological indicators. Postoperative stone recurrence within 6 months was considered the clinical outcome for exploring the risk factors for stone recurrence after FURSL for kidney and ureteral stones.

FURSL without DJ stent placement refers to a single-session procedure wherein stone removal is completed during one operation. FURSL with preoperative DJ stent placement involves a first-stage procedure to insert the DJ stent, followed by FURSL conducted approximately 2 weeks to 2 months later. For planned nonemergent placement, an F6 silicone tube is used, and FURSL is routinely performed 2 weeks after the placement. The operative time is defined as the duration from the insertion of the ureteroscope into the bladder to the placement of the Foley catheter. Intraoperative blood loss is defined as the total volume of blood and irrigation fluid collected in the suction bottle minus the volume of irrigation fluid. Hospitalization duration refers to the total number of days from admission to discharge, including both the preoperative and postoperative periods.

This study was conducted in accordance with the principles of the Declaration of Helsinki (2024 revision) and was approved by the Ethics Committee of Peking University First Hospital–Miyun Hospital (NO.: 2021-04). The need for informed consent was waived for this retrospective analysis. The data presented in this study have been de-identified to remove information that could identify patients.

Surgical technique

The surgeon in this study was a physician with over 20 years of experience in urolithiasis surgery and had performed hundreds of urolithiasis-related procedures. The patient was placed in the lithotomy position under successful anesthesia. Routine disinfection and draping were performed. A 12-F urethral catheter was inserted to drain urine, and a F9.5 flexible ureteroscope was introduced via the urethra into the bladder to inspect and locate the affected ureteral orifice. After inserting a nitinol guidewire, the ureteroscope was withdrawn, and a 12-F hydrophilic access sheath was placed along the guidewire. The ureter and renal pelvis/calyces were inspected. Stones were fragmented using a Holmium laser (1 J, 20 W), and some fragments were extracted with an NGage basket. Powdered fragments were left to pass naturally. After confirming that there were no residual stones with a diameter >2 mm, a DJ stent was placed, and the procedure was concluded.

Statistical analysis

SPSS 22.0 was used for statistical analysis. Normally distributed data were expressed as mean ± standard deviation, while non-normally distributed data were described using median (range). For continuous variables, unpaired t-tests were used for normally distributed data, and the Mann–Whitney U test was used for non-normally distributed data. Fisher’s exact test was used for categorical variables. Univariate and multivariate binary logistic regression analyses (P < 0.05) were performed to identify independent risk factors for stone recurrence following FURSL.

Results

Baseline data

Baseline data of the patients undergoing FURSL are shown in Table 1. A total of 109 patients underwent FURSL for kidney and ureteral stones, with an average age of 52.09 ± 12.53 years. The mean stone diameter was 1.16 ± 0.31 cm. The proportion of patients undergoing FURSL without preoperative DJ stent placement was 37.61% (41/109), while the proportion of those undergoing FURSL with preoperative DJ stent placement was 62.39% (68/109). The overall stone recurrence rate was 8.26% (9/109).

Table 1.

Basic characteristics of the patients.

Variable	Mean (SD) or n/N
Number of patients, n	109
Age (years)	52.09 ± 12.53
BMI (kg/m²)	25.80 ± 3.61
Sex, n (%)
Male	72 (66.06%)
Female	37 (33.94%)
Hypertension, n (%)
No	71 (65.14%)
Yes	38 (34.86%)
Diabetes, n (%)
No	82 (75.23%)
Yes	27 (24.77%)
CHD, n (%)
No	101 (92.66%)
Yes	8 (7.34%)
Side, n (%)
Left	50 (45.87%)
Right	48 (44.04%)
Stone location, n (%)
Kidney	101 (92.66%)
Ureter	8 (7.34%)
Stone removal strategy, n (%)
Nonpreoperative DJ tube group	41 (37.61%)
Preoperative DJ tube group	68 (62.39%)
Stone diameter (cm)	1.16 ± 0.31
Preoperative hemoglobin (g/dL)	139.85 ± 22.25
Preoperative white blood cell count (×10⁹/L)	7.22 ± 7.68
Preoperative creatinine (mg/dL)	78.54 ± 47.03
Preoperative blood sodium (mmol/L)	140.42 ± 1.78
Preoperative blood potassium (mmol/L)	7.79 ± 38.75
Preoperative systolic pressure (mmHg)	127.29 ± 8.49
Preoperative diastolic pressure (mmHg)	77.91 ± 6.21
Preoperative blood calcium (mmol/L)	2.37 ± 0.31
Surgery duration (min)	86.66 ± 41.42
Intraoperative blood loss (mL)	4.52 ± 7.36
Postoperative hemoglobin (g/dL)	133.11 ± 18.46
Postoperative white blood cell count (×10⁹/L)	9.72 ± 8.56
Postoperative creatinine (mg/dL)	81.41 ± 46.68
Postoperative blood sodium (mmol/L)	141.47 ± 2.55
Postoperative blood potassium (mmol/L)	3.99 ± 0.40
Postoperative systolic pressure (mmHg)	128.76 ± 10.37
Postoperative diastolic pressure (mmHg)	77.66 ± 6.89
Postoperative blood calcium (mmol/L)	2.20 ± 0.12
Hospitalization duration (days)	6.67 ± 2.17
Recurrence of stone, n (%)
No	100 (91.74%)
Yes	9 (8.26%)

BMI: body mass index; CHD: coronary heart disease; DJ: double-J.

Comparison of the patients with and without preoperative DJ stent placement

The clinical data of the patients in the preoperative DJ tube group and nonpreoperative DJ tube group are shown in Table 2. The stone recurrence rates in the preoperative and nonpreoperative DJ tube groups were 1.47% (1/68) and 19.51% (8/41), respectively, with a statistically significant difference (P = 0.001). The average ages of the patients in the preoperative and nonpreoperative DJ tube groups were 54.79 ±11.72 and 47.61 ± 12.69 years, respectively, with a statistically significant difference (P = 0.003).

Table 2.

Comparison of stone removal using flexible ureteroscopy between the preoperative and nonpreoperative DJ tube groups.

Variable	Preoperative DJ tube group	Nonpreoperative DJ tube group	P value
Number of patients, n	68	41
Age (years)	54.79 ± 11.72	47.61 ± 12.69	0.003
BMI (kg/m²)	26.05 ± 3.84	25.39 ± 3.19	0.357
Sex, n (%)			0.540
Male	47 (69.12%)	26 (63.41%)
Female	21 (30.88)	15 (36.59%)
Hypertension, n (%)			0.075
No	40 (58.82%)	31 (75.61%)
Yes	28 (41.18%)	10 (24.39%)
Diabetes, n (%)			0.596
No	50 (73.53%)	32 (78.05%)
Yes	18 (26.47%)	9 (21.95%)
CHD, n (%)			0.128
No	61 (89.71%)	40 (97.56%)
Yes	7 (10.29%)	1 (2.44%)
Side, n (%)			0.023
Left	30 (52.63%)	20 (48.78%)
Right	27 (47.37%)	21 (51.22%)
Stone location, n (%)			0.453
Kidney	64 (94.12%)	37 (90.24%)
Ureter	4 (5.88%)	4 (9.76%)
Stone diameter (cm)	1.13 ± 0.31	1.23 ± 0.32	0.218
Preoperative hemoglobin (g/dL)	138.38 ± 22.93	142.29 ± 21.12	0.376
Preoperative white blood cell count (×10⁹/L)	7.66 ± 9.66	6.49 ± 1.44	0.442
Preoperative creatinine (mg/dL)	76.34 ± 32.45	82.31 ± 65.28	0.532
Preoperative blood sodium (mmol/L)	140.53 ± 1.88	140.25 ± 1.60	0.438
Preoperative blood potassium (mmol/L)	10.01 ± 48.74	3.99 ± 0.27	0.443
Preoperative systolic pressure (mmHg)	127.93 ± 9.26	126.24 ± 7.01	0.318
Preoperative diastolic pressure (mmHg)	77.63 ± 6.01	78.37 ± 6.56	0.552
Preoperative blood calcium (mmol/L)	2.38 ± 0.38	2.34 ± 0.15	0.530
Surgery duration (min)	86.43 ± 41.46	87.01 ± 41.87	0.943
Intraoperative blood loss (mL)	4.06 ± 6.43	5.29 ± 8.72	0.399
Postoperative hemoglobin (g/dL)	133.16 ± 17.16	133.02 ± 20.66	0.970
Postoperative white blood cell count (×10⁹/L)	10.31 ± 10.54	8.72 ± 3.18	0.349
Postoperative creatinine (mg/dL)	79.11 ± 30.69	85.12 ± 64.97	0.519
Postoperative blood sodium (mmol/L)	141.42 ± 2.64	141.55 ± 2.41	0.800
Postoperative blood potassium (mmol/L)	3.99 ± 0.42	3.99 ± 0.37	0.909
Postoperative systolic pressure (mmHg)	128.09 ± 11.03	129.88 ± 9.17	0.385
Postoperative diastolic pressure (mmHg)	77.53 ± 7.55	77.88 ± 5.70	0.799
Postoperative blood calcium (mmol/L)	2.20 ± 0.13	2.21 ± 0.12	0.768
Hospitalization duration (days)	6.51 ± 2.37	6.93 ± 1.79	0.34
Recurrence of stone, n (%)			0.001
No	67 (98.53%)	33 (80.49%)
Yes	1 (1.47%)	8 (19.51%)

BMI: body mass index; CHD: coronary heart disease; DJ: double-J.

Analysis of risk factors for stone recurrence following FURSL

The clinical data of the recurrence and nonrecurrence groups are shown in Table 3. The proportions of DJ tube retained before surgery in the recurrence and nonrecurrence groups were 11.11% (1/9) and 67% (67/100), respectively, with a statistically significant difference between the two groups (P = 0.001).

Table 3.

Comparison of stone removal using flexible ureteroscopy between the recurrence and nonrecurrence groups.

Variable	Recurrence group	Nonrecurrence group	P value
Number of patients, n	9	100
Age (years)	47.00 ± 7.12	52.55 ± 12.83	0.205
BMI (kg/m²)	24.27 ± 3.65	25.94 ± 3.59	0.184
Sex, n (%)			0.134
Male	4 (44.44%)	69 (69%)
Female	5 (55.56%)	31 (31%)
Hypertension, n (%)			0.119
No	8 (88.89%)	63 (63%)
Yes	1 (11.11%)	37 (37%)
Diabetes, n (%)			0.072
No	9 (100%)	73 (73%)
Yes	0 (0%)	27 (27%)
CHD, n (%)			0.378
No	9 (100%)	92 (92%)
Yes	0 (0%)	8 (8%)
Side, n (%)			0.987
Left	4 (50%)	46 (51.11%)
Right	4 (50%)	44 (48.89%)
Stone location, n (%)			0.651
Kidney	8 (88.89%)	93 (93%)
Ureter	1 (11.11%)	7 (7%)
Stone removal strategy, n (%)			0.001
Nonpreoperative DJ tube group	8 (88.89%)	33 (33.00%)
Preoperative DJ tube group	1 (11.11%)	67 (67.00%)
Stone diameter (cm)	1.36 ± 0.21	1.15 ± 0.31	0.136
Preoperative hemoglobin (g/dL)	141.56 ± 21.81	139.70 ± 22.39	0.812
Preoperative white blood cell count (×10⁹/L)	6.52 ± 1.36	7.28 ± 8.01	0.777
Preoperative creatinine (mg/dL)	63.22 ± 16.56	79.96 ± 48.71	0.309
Preoperative blood sodium (mmol/L)	140.18 ± 1.83	140.45 ± 1.78	0.668
Preoperative blood potassium (mmol/L)	4.03 ± 0.26	8.14 ± 40.51	0.762
Preoperative systolic pressure (mmHg)	120.89 ± 5.26	127.87 ± 8.50	0.017
Preoperative diastolic pressure (mmHg)	78.56 ± 4.95	77.85 ± 6.32	0.746
Preoperative blood calcium (mmol/L)	2.33 ± 0.10	2.37 ± 0.33	0.745
Surgery duration (min)	103.11 ± 28.14	85.16 ± 42.21	0.215
Intraoperative blood loss (mL)	10.33 ± 15.33	4.00 ± 6.06	0.013
Postoperative hemoglobin (g/dL)	129.56 ± 13.82	133.43 ± 18.84	0.549
Postoperative white blood cell count (×10⁹/L)	9.03 ± 4.18	9.78 ± 8.86	0.804
Postoperative creatinine (mg/dL)	68.78 ± 21.05	82.57 ± 48.26	0.399
Postoperative blood sodium (mmol/L)	141.48 ± 3.01	141.47 ± 2.52	0.991
Postoperative blood potassium (mmol/L)	3.90 ± 0.28	4.00 ± 0.41	0.476
Postoperative systolic pressure (mmHg)	127.78 ± 7.86	128.85 ± 10.59	0.768
Postoperative diastolic pressure (mmHg)	75.67 ± 3.32	77.84 ± 7.10	0.367
Postoperative blood calcium (mmol/L)	2.22 ± 0.10	2.20 ± 0.12	0.747
Hospitalization duration (days)	7.33 ± 1.41	6.61 ± 2.22	0.341

BMI: body mass index; CHD: coronary heart disease; DJ: double-J.

The preoperative systolic blood pressure levels were 120.89 ± 5.26 and 127.87 ± 8.50 mmHg in the recurrence and nonrecurrence groups, respectively, with a statistically significant difference between the two groups (P = 0.017). The intraoperative blood losses were 10.33 ± 15.33 and 4.00 ± 6.06 mL in the recurrence and nonrecurrence groups, respectively, with a statistically significant difference between the two groups (P = 0.013).

Univariate regression analysis identified stone removal strategy (P < 0.001), preoperative systolic blood pressure (P = 0.017), and intraoperative blood loss (P = 0.044) as risk factors for recurrence. Multivariate regression analysis confirmed stone removal strategy (P = 0.013) and preoperative systolic blood pressure (P = 0.017) as independent risk factors (Table 4).

Table 4.

Univariate and multivariate regression analyses of the recurrence of kidney and ureteral stones treated with flexible ureteroscopy.

	Univariate analysis		Multivariate analysis
Characteristics	HR (95% CI)	P value	HR (95% CI)	P value
Age	0.965 (0.912–1.020)	0.207
BMI	0.855 (0.686–1.065)	0.162
Sex	0.359 (0.090–1.431)	0.147
Hypertension	4.698 (0.565–39.070)	0.152
Side	0.870 (0.088–8.635)	0.905
Stone location	0.602 (0.066–5.523)	0.654
Stone removal strategy	16.242 (1.949–135.349)	0.01	29.756 (2.057–430.357)	0.013
Stone diameter	6.940 (0.520–92.680)	0.143
Preoperative hemoglobin	1.004 (0.971–1.038)	0.809
Preoperative white blood cell count	0.972 (0.778–1.214)	0.801
Preoperative creatinine	0.968 (0.927–1.011)	0.148
Preoperative blood sodium	0.919 (0.628–1.346)	0.664
Preoperative blood potassium	0.981 (0.495–1.942)	0.956
Preoperative systolic pressure	0.885 (0.800–0.979)	0.017	0.824 (0.703–0.966)	0.017
Preoperative diastolic pressure	1.018 (0.915–1.132)	0.743
Preoperative blood calcium	0.541 (0.013–21.803)	0.744
Surgery duration	1.009 (0.994–1.024)	0.220
Intraoperative blood loss	1.061 (1.002–1.123)	0.044	1.066 (0.983–1.156)	0.122
Hospitalization duration	1.132 (0.875–1.463)	0.345

BMI: body mass index; HR: hazard ratio; CI: confidence interval.

Discussion

Urinary stone disease is one of the most common diseases of the urinary system, with an incidence of 5%–10% in China, which has been gradually increasing.¹² FURSL is widely used owing to its minimal invasiveness, high efficiency, and broad indications, and it has become the treatment of choice for kidney stones with a diameter of 1–2 cm in patients who cannot undergo PCNL.¹³ Several studies have shown that preoperative DJ stent placement can improve the stone clearance rate through FURSL and reduce the risk of systemic inflammatory response syndrome.^10,11,14

Currently, the mainstream treatment methods for urinary stones include PCNL and FURSL. Extracorporeal shock wave lithotripsy (ESWL) plays a key role in the management of urinary tract stones. Although ESWL is considered the only noninvasive treatment, it is less effective for larger stones (generally >2 cm) compared with other methods, requiring multiple sessions and often causing complications such as pain and hematuria during the process.^15,16 PCNL is more efficient in cases of large (>2 cm) or complex stones. It not only removes stones but also helps protect renal function in patients with chronic kidney disease. However, PCNL requires higher technical skill and is more invasive. For stones smaller than 2 cm, FURSL may have more advantages. With its low incidence of postoperative complications and low cost, FURSL has surpassed both ESWL and PCNL and emerged as the mainstream method for treating kidney and urinary tract stones. Although FURSL is an advanced surgical technique, further improvement is warranted in certain areas.

It remains controversial whether preoperative DJ stent placement affects stone recurrence after FURSL. DJ stents play an important role in the treatment of kidney stones, ureteral stones, and benign tumors of the kidney and ureter. Preoperative DJ stent placement can expand the ureter to facilitate stone removal, preventing damage to the ureter during the procedure and reducing postoperative complications such as infections and ureteral obstruction. Many surgeries are affected by limited visibility during the procedure, and placing a DJ stent preoperatively can help expand the ureter, improve visibility, and enhance the convenience of the procedure. This also reduces the occurrence of ureteral strictures, allowing better access for surgical instruments, thereby improving the efficiency of the surgery. Preoperative DJ stent placement has shown advantages in improving the postoperative quality of life and increasing the success rate of surgery, as it can effectively prevent the retention of stone fragments in the ureter, promoting their smooth elimination due to the expanded ureter and reducing the likelihood of requiring a second surgery.^17–21

DJ stents are an important tool in urology; however, certain complications, such as displacement, hematuria, and infections, have been reported with their widespread use. Geavlete et al.²² retrospectively analyzed 50,000 surgeries performed on 36,688 patients between 1996 and 2021. They reported 41,369 complications, including 153 cases (0.3%) of stent misplacement, 779 cases (1.6%) of stent displacement (427 of which were proximal and 352 were distal), 5213 cases (10.4%) of hematuria, and 7436 cases (14.9%) of urinary tract infections. Additionally, Altay et al.²³ reported a case of renal parenchymal perforation caused by DJ stent placement after ureteroscopic surgery, alongside other adverse reactions associated with stent placement. Preoperative DJ stent placement may lead to local irritation and mild damage to the ureteral mucosa, which can disrupt the integrity of the epithelial cells and induce an inflammatory response. This creates a microenvironment that is more favorable for stone adhesion. Furthermore, bacteria tend to colonize the stent surface, forming biofilms over time. The bacteria within the biofilms metabolize and produce urea nitrogen, which alkalinizes the urine. In an alkaline environment, calcium phosphate crystals are more likely to accumulate and form stones.^24–26

This study did not explore the complications arising from DJ stent placement but focused on analyzing the impact of preoperative DJ stent placement on stone recurrence after FURSL. Our findings suggest that preoperative DJ stent placement is beneficial in reducing the recurrence of stones after surgery. We hypothesize that the stent helps maintain urinary tract patency, relieves obstruction, reduces postoperative urinary retention, lowers the risk of urinary tract infections and inflammation, and promotes the expulsion of stone fragments. Additionally, the stent helps prevent postoperative ureteral stricture or scarring, particularly after large or complex stone surgeries, reducing the likelihood of recurrence.

In this study, we found that preoperative systolic blood pressure is a risk factor for stone recurrence following FURSL. High preoperative systolic blood pressure is partly attributed to preoperative anxiety and chronic hypertension. Even without a formal diagnosis of hypertension, elevated systolic blood pressure indicates metabolic and renal function imbalance, increasing the risk of stone recurrence through changes in renal blood flow, metabolic disturbances, oxidative stress, and inflammation. Zhou et al.²⁷ conducted a study that demonstrated an association between the recurrence of ureteral stones and metabolic syndrome, such as high systolic blood pressure. The possible mechanism is the alteration of renal hemodynamics, which increases renal perfusion pressure, leading to increased glomerular pressure and damage to the glomerular filtration barrier. This change can affect the urine composition, leading to increased excretion of substances such as calcium and oxalate, which increases the risk of stone formation.^28,29 Patients with elevated preoperative systolic blood pressure should undergo strict preoperative metabolic evaluation and postoperative follow-up, with adjustments to diet and lifestyle, for treating potential metabolic disorders and reducing stone recurrence.

We also identified intraoperative blood loss as a risk factor for stone recurrence in the univariate analysis. Blood loss may lead to insufficient local renal blood supply, impairing renal function and disrupting the kidney’s ability to regulate urine composition, leading to higher concentrations of stone-forming substances (such as calcium, oxalate, and uric acid) and increasing the risk of stone recurrence.

Previous studies have suggested that diabetes is a significant factor influencing stone recurrence after surgery, but no such relationship was found in this study. Diabetes affects the kidneys in multiple ways, i.e. through the glomerulus, renal tubules, or urinary system.^30,31 Papachristoforou et al.³² described how prolonged hyperglycemia can induce oxidative stress and inflammation through NF-kB-mediated pathways, directly damaging renal structures. This study did not find a significant correlation between diabetes and stone recurrence, which may be attributed to the limited sample size and follow-up period.

Our study has several limitations. First, it is a single-center study, and the limited sample size may have introduced bias in the results. Second, this study used a retrospective analysis approach, and all factors influencing stone recurrence after FURSL may not have been included in the data collection process, particularly variables highly correlated with stone recurrence, such as stone composition and metabolic evaluation data. Prospective studies are warranted in the future to incorporate key variables such as stone composition, metabolic evaluation data, and renal function while increasing the sample size.

Conclusion

Preoperative DJ stent placement significantly reduces stone recurrence after FURSL compared with no stent placement. Stone removal strategy and preoperative systolic blood pressure are independent risk factors for stone recurrence after FURSL.

Footnotes

Acknowledgment

None.

Author contributions

Conception and design: Chao Zuo, Yue Li, Yaming Gu

Administrative support: Chao Zuo, Yue Li, Yaming Gu

Provision of study materials or patients: Chao Zuo, Yue Li, Zihui Gao, Yaming Gu

Collection and assembly of data: Chao Zuo

Data analysis and interpretation: Chao Zuo

Manuscript writing: All authors

Final approval of the manuscript: All authors

Consent to participate

The need for informed consent was waived due to the retrospective design of the study.

Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Declaration of conflicting interests

None declared.

Ethical approval

The trial was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the Ethics Committee of Peking University First Hospital–Miyun Hospital (NO.: 2021-04).

Funding

None.

ORCID iDs

Zihui Gao

Yaming Gu

References

Qiu

Shi

Yang

, et al. Comparison of the efficacy and safety of mini-percutaneous nephrolithotomy versus retrograde intrarenal surgery for the treatment of kidney stones in overweight or obese patients: a systematic review and meta-analysis. BMC Urol 2024; 24: 243.

Kong

Johnson

Maalouf

, et al. Predicting urinary stone recurrence: a joint model analysis of repeated 24-hour urine collections from the MSTONE database. Urolithiasis 2024; 52: 156.

Wang

Yang

, et al. Surgical procedure and recurrence of upper urinary tract stone: a national-wide study based on hospitalized patients. World J Urol 2024; 42: 132.

Dhondup

Kittanamongkolchai

Vaughan

, et al. Risk of ESRD and mortality in kidney and bladder stone formers. Am J Kidney Dis 2018; 72: 790–797.

Zhang

Leng

Xie

, et al. Flexible ureteroscopic lithotripsy with a suctioning ureteral access sheath for removing upper urinary calculi under local anesthesia. Front Surg 2023; 10: 1242981.

Pan

Zhang

Pan

, et al. A retrospective analysis on the effect of single-channel minimally invasive percutaneous nephrolithotomy combined with retrograde flexible ureteroscopy using the completely lateral decubitus and semi-lithotomy positions to treat complex kidney stones. Transl Androl Urol 2021; 10: 3638–3645.

Agrawal

Agarwal

Jindal

, et al. Ultra-mini-percutaneous nephrolithotomy: a minimally-invasive option for percutaneous stone removal. Indian J Urol 2016; 32: 132–136.

Hyams

Shah

Percutaneous nephrostolithotomy versus flexible ureteroscopy/Holmium laser lithotripsy: cost and outcome analysis. J Urol 2009; 182: 1012–1017.

Chang

Ding

, et al. The clinical efficacy of percutaneous nephrolithotomy and flexible ureteroscopic lithotripsy in the treatment of calyceal diverticulum stones: a meta-analysis. Arch Esp Urol 2022; 75: 423–429.

10.

Shields

Bird

Graves

, et al. Impact of preoperative ureteral stenting on outcome of ureteroscopic treatment for urinary lithiasis. J Urol 2009; 182: 2768–2774.

11.

Yuk

Park

Cho

, et al. The effect of preoperative ureteral stenting in retrograde intrarenal surgery: a multicenter, propensity score-matched study. BMC Urol 2020; 20: 147.

12.

Azab

Osama

Factors affecting lower calyceal stone clearance after extracorporeal shock wave lithotripsy. African Journal of Urology 2013; 19: 13–17.

13.

Xia

Xuan

Cao

, et al. Computational analysis of influencing factors and multiple scoring systems of stone clearance rate after flexible ureteroscopic lithotripsy. Comput Intell Neurosci 2022; 2022: 7879819.

14.

Qian

Liu

Hong

, et al. Application of suctioning ureteral access sheath during flexible ureteroscopy for renal stones decreases the risk of postoperative systemic inflammatory response syndrome. Int J Clin Pract 2022; 2022: 9354714.

15.

Lawler

Ghiraldi

Tong

, et al. Extracorporeal shock wave therapy: current perspectives and future directions. Curr Urol Rep 2017; 18: 25.

16.

Mosquera Seoane

Ortiz Salvador

Budia Alba

, et al. Technological innovations in shock wave lithotripsy. Actas Urol Esp (Engl Ed) 2024; 48: 105–110.

17.

Mehra

Satpathy

Joshi

, et al. Percutaneous nephrolithotomy in patients with chronic kidney disease: a systematic review. Urol Int 2022; 106: 461–468.

18.

Muslumanoglu

Fuglsig

Frattini

, et al. Risks and benefits of postoperative double-J stent placement after ureteroscopy: results from the Clinical Research Office of Endourological Society Ureteroscopy Global Study. J Endourol 2017; 31: 446–451.

19.

Wang

Xie

, et al. Novel use of a modified triangular prismatic double-J stent for 2- to 3-cm renal stones after one-stage retrograde intrarenal surgery. Urol Int 2021; 105: 594–599.

20.

Al Demour

Alrabadi

AlSharif

, et al. Ureteric stenting vs not stenting following uncomplicated ureteroscopic lithotripsy: a prospective randomised trial. Arab J Urol 2020; 18: 169–175.

21.

Zimskind

Fetter

Wilkerson

JL.

Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 1967; 97: 840–844.

22.

Geavlete

Georgescu

Mulţescu

, et al. Ureteral stent complications – experience on 50,000 procedures. J Med Life 2021; 14: 769–775.

23.

Altay

Erkurt

Kiremit

, et al. A rare complication of ureteral double-J stenting after flexible ureteroscopy: renal parenchymal perforation. Turk J Urol 2015; 41: 96–98.

24.

Kaliyeva

Simokhina

Lavrinenko

, et al. Bacterial colonization incidence before and after indwelling double-J ureteral stents. Antibiotics 2022; 11: 850.

25.

Plongla

Preece

Perry

, et al. Evaluation of RGM medium for isolation of nontuberculous mycobacteria from respiratory samples from patients with cystic fibrosis in the United States. J Clin Microbiol 2017; 55: 1469–1477.

26.

Betschart

Zumstein

Buhmann

, et al. Symptoms associated with long-term double-J ureteral stenting and influence of biofilms. Urology 2019; 134: 72–78.

27.

Zhou

Ouyang

Zhang

ZY.

Analysis and prediction of postoperative recurrence of unilateral upper ureteral calculi in 243 cases (nomogram). SAGE Open Med 2023; 11: 20503121231191995.

28.

Zhang

Sun

Wang

, et al. The association between hypertension and the risk of gallstone disease: a cross-sectional study. BMC Gastroenterol 2022; 22: 138.

29.

Chu

Chang

Huang

, et al. The association of uric acid calculi with obesity, prediabetes, type 2 diabetes mellitus, and hypertension. Biomed Res Int 2017; 2017: 7523960.

30.

Mosenzon

Wiviott

Cahn

, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7: 606–617.

31.

Scheen

AJ.

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes Metab 2019; 45: 110–121.

32.

Papachristoforou

Lambadiari

Maratou

, et al. Association of glycemic indices (hyperglycemia, glucose variability, and hypoglycemia) with oxidative stress and diabetic complications. J Diabetes Res 2020; 2020: 7489795.

Impact of preoperative double-J stent placement on stone recurrence following flexible ureteroscopic lithotripsy

Abstract

Objective

Methods

Results

Conclusions

Keywords

Introduction

Methods

Study population

Surgical technique

Statistical analysis

Results

Baseline data

Comparison of the patients with and without preoperative DJ stent placement

Analysis of risk factors for stone recurrence following FURSL

Discussion

Conclusion

Footnotes

Acknowledgment

Author contributions

Consent to participate

Data availability

Declaration of conflicting interests

Ethical approval

Funding

ORCID iDs

References